Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi (SAN)’s head of diabetes medicine sales has left the company, weeks after the drugmaker fired its CEO and said revenue from its best-selling insulin will be flat next year, according to people familiar with the matter.
Bob Rossilli, who worked at the Paris-based company’s offices in Bridgewater, New Jersey, left his job the week of Nov. 17, said the people, who asked not to be identified discussing private company matters.
Jack Cox, a spokesman for Sanofi, confirmed that the executive left and declined to comment on reasons for the departure. Rossilli couldn’t immediately be reached for comment. Diabetes sales are now overseen by Scott Oehrlein, vice president and head of general medicines sales, Cox said.
http://www.bloomberg.com/news/2014-...ief-said-to-leave-after-insulin-forecast.html
Bob Rossilli, who worked at the Paris-based company’s offices in Bridgewater, New Jersey, left his job the week of Nov. 17, said the people, who asked not to be identified discussing private company matters.
Jack Cox, a spokesman for Sanofi, confirmed that the executive left and declined to comment on reasons for the departure. Rossilli couldn’t immediately be reached for comment. Diabetes sales are now overseen by Scott Oehrlein, vice president and head of general medicines sales, Cox said.
http://www.bloomberg.com/news/2014-...ief-said-to-leave-after-insulin-forecast.html